Alector, Inc. logo ALEC - Alector, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 9
HOLD 3
SELL 2
STRONG
SELL
0
| PRICE TARGET: $2.00 DETAILS
HIGH: $2.00
LOW: $2.00
MEDIAN: $2.00
CONSENSUS: $2.00
UPSIDE: 24.22%

About Alector, Inc. (https://www.alector.com)

Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Additionally, AL101 is progressing through Phase I clinical trials for general neurodegenerative diseases, with a specific focus on Alzheimer's and Parkinson's. Further bolstering its Alzheimer's portfolio, Alector is evaluating AL002 in Phase II studies and AL003 in Phase I studies, both aimed at addressing Alzheimer's disease. In earlier-stage development, the company is also developing AL044, which targets the MS4A4A gene, identified as a risk factor for Alzheimer's disease. Alector has forged key partnerships to advance its mission. It collaborates with Adimab, LLC on antibody research and development. Furthermore, a significant strategic alliance with GlaxoSmithKline plc (GSK) focuses on the joint development and commercialization of monoclonal antibodies, specifically AL001 and AL101, for neurodegenerative conditions. Established in 2013, Alector's headquarters are located in South San Francisco, California.

Key Executives

NAME TITLE DOB SALARY
Arnon Rosenthal Co-Founder, Chief Executive Officer & Director 1956 $1,013,926 USD
Giacomo Salvadore Chief Medical Officer $752,171 USD
Neil Berkley CFO & Chief Business Officer 1974 $705,122 USD
Clare Hunt Chief People & Places Officer
Danielle Pasqualone General Counsel
Eric Brown Director of Antibody Discovery & Protein Engineering
Hua Long DABT Senior VP & Head of Research
Katie Hogan Senior Director of Corporate Communication & Investor Relations
Kristina Cutter Chief Development Officer

Company Peers

Peer analysis pending, check back in 1-2 minutes.